BACKGROUND: To date, serological markers to monitor melanoma progression and response to therapy are lacking. In this context cytokines appear to be promising biomarkers of the disease. OBJECTIVE: To compare cytokine and chemokine levels in melanoma patients and in healthy controls and to assess possible variations according to melanoma stage. METHODS: Serum chemokine and cytokine levels were determined by ELISA in 34 patients diagnosed histologically of malignant melanoma. Seven healthy volunteers were used as controls. RESULTS: We found a subset of cytokines (CCL3, CCL4, IFN-γ and IL-10) to be significantly higher in melanoma patients than in control group, thus confirming the importance of the inflammation in cancer. While CCL3 increased with tumor progression, IFN-γ and IL-10 showed higher levels in stage I patients. Moreover, we noticed a direct correlation between CCL3 level and the presence of ulceration in the primary tumor; on the contrary, CCL4, IL-10 and IFN-γ were lowered down in patients with ulcerated melanoma. CONCLUSIONS: These results expand and confirm observations made in other studies focusing on a more limited number of molecules. This extended panel of cytokines examines the potential roles of type2 cytokines (such as IL-4) and many chemokines (mainly CCL3) as biomarkers in melanoma progression.

Serological landscape of cytokines in cutaneous melanoma / Paganelli, A.; Garbarino, F.; Toto, P.; Martino, G. D.; D'Urbano, M.; Auriemma, M.; Giovanni, P. D.; Panarese, F.; Staniscia, T.; Amerio, P.; Paganelli, R.. - In: DISEASE MARKERS. SECTION A, CANCER BIOMARKERS. - ISSN 1574-0153. - 26:3(2019), pp. 333-342. [10.3233/CBM-190370]

Serological landscape of cytokines in cutaneous melanoma

Paganelli A.;Garbarino F.;
2019

Abstract

BACKGROUND: To date, serological markers to monitor melanoma progression and response to therapy are lacking. In this context cytokines appear to be promising biomarkers of the disease. OBJECTIVE: To compare cytokine and chemokine levels in melanoma patients and in healthy controls and to assess possible variations according to melanoma stage. METHODS: Serum chemokine and cytokine levels were determined by ELISA in 34 patients diagnosed histologically of malignant melanoma. Seven healthy volunteers were used as controls. RESULTS: We found a subset of cytokines (CCL3, CCL4, IFN-γ and IL-10) to be significantly higher in melanoma patients than in control group, thus confirming the importance of the inflammation in cancer. While CCL3 increased with tumor progression, IFN-γ and IL-10 showed higher levels in stage I patients. Moreover, we noticed a direct correlation between CCL3 level and the presence of ulceration in the primary tumor; on the contrary, CCL4, IL-10 and IFN-γ were lowered down in patients with ulcerated melanoma. CONCLUSIONS: These results expand and confirm observations made in other studies focusing on a more limited number of molecules. This extended panel of cytokines examines the potential roles of type2 cytokines (such as IL-4) and many chemokines (mainly CCL3) as biomarkers in melanoma progression.
26
3
333
342
Serological landscape of cytokines in cutaneous melanoma / Paganelli, A.; Garbarino, F.; Toto, P.; Martino, G. D.; D'Urbano, M.; Auriemma, M.; Giovanni, P. D.; Panarese, F.; Staniscia, T.; Amerio, P.; Paganelli, R.. - In: DISEASE MARKERS. SECTION A, CANCER BIOMARKERS. - ISSN 1574-0153. - 26:3(2019), pp. 333-342. [10.3233/CBM-190370]
Paganelli, A.; Garbarino, F.; Toto, P.; Martino, G. D.; D'Urbano, M.; Auriemma, M.; Giovanni, P. D.; Panarese, F.; Staniscia, T.; Amerio, P.; Paganelli, R.
File in questo prodotto:
File Dimensione Formato  
cbm--1-cbm190370.pdf

non disponibili

Tipologia: Post-print dell'autore (bozza post referaggio)
Dimensione 1.21 MB
Formato Adobe PDF
1.21 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11380/1271141
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 2
social impact